Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00290_DB01097_nanopub.RA0KndVSyGFQG6xVNjxQqvjf4YYqqVcGv_BS95O6jIG4Y#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00290_DB01097 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00290_DB01097 label "DDI between Bleomycin and Leflunomide - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. [drugbank_resource:DB00290_DB01097]" assertion.
- drugbank_resource:DB00290_DB01097 identifier "drugbank_resource:DB00290_DB01097" assertion.
- drugbank_resource:DB00290_DB01097 title "DDI between Bleomycin and Leflunomide - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity." assertion.
- drugbank:DB00290 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00290_DB01097 assertion.
- drugbank:DB01097 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00290_DB01097 assertion.